SCHEMBL4511295

SCHEMBL4511295

CC1(O)CCC(N2CCC(Cc3ccc(OCC(=O)NCc4ccccn4)cc3Cl)C2=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
POLB P06746 3/20 0.41
PKM P14618 2/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
EPHX2 P34913 1/20 0.39
P2RX7 Q99572 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509276 0.89 ALDH1A1 (0.40) KMT2AALDH1A1HPGDGAAKDM4E
SCHEMBL5543837 0.87 P2RX7 (0.43) EPHX2P2RX7
SCHEMBL4510722 0.87 ALDH1A1 (0.47) KMT2AALDH1A1HPGDGAAHSD17B10
SCHEMBL4508294 0.86 ALDH1A1 (0.43) MEN1KMT2AALDH1A1HPGDGAA
SCHEMBL4504293 0.85 ALDH1A1 (0.41) MEN1KMT2AALDH1A1GAAPOLB
SCHEMBL4511140 0.85 ALDH1A1 (0.46) MAPTKMT2AALDH1A1HPGDHSD17B10
SCHEMBL4511135 0.84 ATF4 (0.47) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4509399 0.83 MCL1 (0.39) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL4513448 0.83 HSD11B1 (0.49) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL13674510 0.83 ALDH1A1 (0.38) MAPTMEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 MAPT 4692/4885MEN1 1254/4885KMT2A 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.